Logo

Sage and Biogen Presents Results of Zuranolone in LANDSCAPE Clinical Program for Major Depressive Disorder at ACNP 2021

Share this
Sage and Biogen Presents Results of Zuranolone in LANDSCAPE Clinical Program for Major Depressive Disorder at ACNP 2021

Sage and Biogen Presents Results of Zuranolone in LANDSCAPE Clinical Program for Major Depressive Disorder at ACNP 2021

Shots:

  • The companies reported the new data from the LANDSCAPE clinical program including (SHORELINE) & (WATERFALL) studies evaluates zuranolone in patients with MDD
  • In the (WATERFALL) study, the therapy showed improvements in depressive & anxiety symptoms as early as the first measured time point (Day 3 for HAMD-17 & Day 8 for HAM-A), rapid onset of effect in HAMD-17 was observed over PBO as early as Day 3, safety data were consistent with the safety profile across the LANDSCAPE program
  • In the (SHORELINE) Study, the therapy showed similar efficacy & safety results in the datasets analyzed to that observed in a general study population, was well-tolerated in a subgroup of patients aged ≥65yrs.

/ article | Ref: Businesswire | Image: Sagerx

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions